Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors

@article{Harten1993ClinicalPO,
  title={Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors},
  author={J. Harten},
  journal={Clinical Pharmacokinetics},
  year={1993},
  volume={24},
  pages={203-220}
}
  • J. Harten
  • Published 1993
  • Biology
  • Clinical Pharmacokinetics
SummaryA feature common to all selective serotonin reuptake inhibitors (SSRIs) is that they are believed to act as antidepressant drugs because of their ability to reversibly block the reuptake of serotonin (5-hydroxytryptamine; 5-HT) in the synaptic cleft. From a chemical perspective, however, they show distinct differences. Consequently, the pharmacokinetic behaviour of the drugs can be very different, and these pharmacokinetic differences may have a major influence on their clinical profiles… Expand
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
  • S. Preskorn
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 1997
TLDR
An overview of the clinically relevant pharmacology of selective serotonin reuptake inhibitors (SSRIs) with an emphasis on their pharmacokinetics and effects on cytochrome P450 (CYP) enzymes is presented. Expand
Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.
TLDR
It is found that several SRIs can interfere with the activity of a major drug-metabolizing pathway, the human hepatic microsomal cytochrome P-450-2D6 isozyme, in vitro, and in vitro data are suggestive of clinical studies of the effects of SRIs other than fluoxetine on TCA metabolism. Expand
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
TLDR
There are important clinical differences among the SSRIs in their pharmacokinetic characteristics including differences in their half-lives, linear versus non-linear pharmacokinetics, effect of age on their clearance and their potential to inhibit drug metabolising cytochrome P450 (CYP) isoenzymes. Expand
Pharmacokinetics of selective serotonin reuptake inhibitors.
TLDR
Different pharmacokinetic properties of the five SSRIs, especially their drug-drug interaction potential, should be considered when selecting a distinct SSRI for treatment of depression or other disorders with a suggested dysfunction of the serotonergic system in the brain. Expand
Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.
TLDR
Knowing about pharmacokinetic profiles of SSRIs will enable clinicians to predict and make appropriate dose adjustments to avoid potential drug-drug interactions that otherwise could result in toxicity. Expand
Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors
TLDR
No clearcut plasma concentration-clinical effectiveness relationship in patients with depression has been shown, nor any threshold which defines toxic concentrations, and SSRIs presently available may be explained by their low toxicity and use at dosages where serious adverse effects do not appear. Expand
Drug Interactions of Clinical Significance with Selective Serotonin Reuptake Inhibitors
TLDR
This article details those medications that may interact significantly with the SSRIs, and provides clinical guidelines for minimising the likelihood of such complications. Expand
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
TLDR
Although no clear relationship exists between the clinical efficacy, plasma concentration of SSRIs, nor any threshold that defines toxic concentrations, therapeutic drug monitoring (TDM) may be useful in special populations, such as in elderly patients, poor metabolizers (PM) of sparteine or mephenytoin (CYP2C19), and patients with liver and kidney impairment. Expand
The pharmacogenetics of the selective serotonin reuptake inhibitors
  • K. Brøsen
  • Chemistry, Medicine
  • The clinical investigator
  • 2004
TLDR
Citalopram and fluoxetine are administered as racemates, but practically nothing is known about the stereoselective metabolism of the two drugs. Expand
SSRI differentiation: Pharmacology and pharmacokinetics
TLDR
Differences in potency at inhibiting serotonin reuptake and the suitability of individual SSRIs in special patient groups are apparent and it is worthwhile to be made aware of possible interactions between drugs that act as inhibitors or substrates of the hepatic cytochrome P450 system. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
TLDR
Preliminary data suggest that citalopram may be particularly useful in patients who cannot tolerate the anticholinergic or cardiovascular side effects of tricyclic antidepressants and in those for whom sedation is not indicated. Expand
Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
TLDR
Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients. Expand
Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin
TLDR
In these studies, paroxetine and the individual interacting drugs were administered repeatedly prior to pharmacokinetic analyses, to achieve distribution equilibrium during the measurement intervals, and plasma levels of warfarin and digoxin were determined in order to assess the effect of parxetine on the steadystate disposition of these agents. Expand
Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
TLDR
Overall, available data appear to indicate that while the efficacy of paroxetine is similar to that of traditional antidepressant drugs, the newer agent possesses much improved tolerability and may be beneficial when treating patients with an increased risk of suicide. Expand
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
TLDR
It is suggested that compounds with SSRI activity are likely to interact with human CYP2D6 in vivo with the potential of causing drug interactions. Expand
Fluoxetine disposition and elimination in cirrhosis
TLDR
It is shown that in stable alcoholic cirrhosis, the elimination of fluoxetine is significantly reduced and the formation of norfluoxETine was decreased and its clearance was also reduced, meaning that at steady state both fluoxettine and norfluxetine concentrations will be higher in patients with cirrhotic disease, unless the dosage is reduced. Expand
Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake.
TLDR
Ki's for blocking uptake of norepinephrine, serotonin, and dopamine into synaptosomal preparations of rat brain were determined for 25 antidepressants and putative antidepressants, some neuroleptics, stimulants, antihistamines and other monoamines to compare the relative potencies of a drug at the three processes. Expand
Inhibition of serotonin uptake by optical isomers of fluoxetine
The optical isomers of fluoxetine, a selective inhibitor of serotonin (5‐hydroxytryptamine, 5HT) uptake, have been compared pharmacologically. As inhibitors of 3H‐5HT uptake in cortical synaptosomesExpand
Antidepressants, Metabolites, and Apparent Drug Resistance
TLDR
Antidepressant drugs are extensively metabolized prior to elimination from the body, usually having biological and chemical properties different from those of the parent drug. Expand
Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.
TLDR
Fluoxetine has been greeted with an enthusiasm that claims some advantages over other antidepressants, but any unique therapeutic benefits may be accompanied by a unique adverse effects profile and a special propensity for drug-drug interactions. Expand
...
1
2
3
4
5
...